BURRELL INTERNATIONAL GROUP LLC

Lobbying for AMO PHARMA, LTD. · Biopharmaceutical research and development

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $50,000.00 income · posted Jan 14, 2026

Lobbying activity 1

Health Issues

Rare Disease Policy and FDA Policy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem